The company’s next move will depend on whether subgroup signals can survive a confirmatory trial.

Glenmark's Ryaltris has reached Brazil ahead of schedule, bringing the allergy nasal spray to what the firm describes as the ...

While celebrating the near half-trillion dollars in US savings achieved by using generics and biosimilars in 2025, the AAM’s ...

Handa’s Omcazio hybrid drug has won final US approval after Exelixis dropped its patent suit and failed to persuade the FDA to block the 505(b)(2) product, opening another route into the blockbuster ...

Humana is seeking to lift a 45-day stay on its generic price-fixing bellwether against Mylan and Lannett, as the parties clash over whether special discovery master Lawrence Stengel should remain ...

A Canadian court has refused to dismiss an ongoing class action lawsuit against Gilead Sciences over alleged negligence claims relating to its HIV drug, a decision that could “significantly reshape” ...

Arizona’s lawsuit against L’Oréal USA, Inc. and associated companies alleges the company concealed cancer risks tied to chemical hair relaxers marketed to women and girls of African descent.

Abbott closes one door on its infant formula problems linked to a widespread recall and supply crisis in the US but still faces class action complaints alleging harm from the products.

Peerbridge plans to introduce its newly FDA-cleared second-generation Cor MDx patch for detecting heart arrythmias to health ...

Strong PFS data and oral convenience may enable zipalertinib to compete against J&J’s bispecific Rybrevant in NSCLC patients ...

The US FDA approved the myostatin inhibitor Isembyld (apitegromab) on top of SMN-targeted therapies for spinal muscular ...

AstraZeneca and Daiichi Sankyo’s HER2-targeting ADC showed a PFS benefit in first-line treatment of HER2-mutant non-small ...